• Kailash Krishnan, Zhe Kang Law, Jatinder S Minhas, Philip M Bath, Thompson G Robinson, Nikola Sprigg, Akash Mavilakandy, Timothy J England, David Eveson, Amit Mistri, Jesse Dawson, and Jason P Appleton.
• Queen's Medical Centre, Nottingham, UK kailash.krishnan@nuh.nhs.uk.
• Clin Med (Lond). 2022 Sep 1; 22 (5): 449454449-454.

AbstractAcute stroke is the leading cause of disability in the UK and a leading cause of mortality worldwide. The majority of patients with ischaemic stroke present with minor deficits or transient ischaemic attack (TIA), and are often first seen by patient-facing clinicians. Urgent evaluation and treatment are important as many patients are at high risk of major vascular events and death within hours to days after the index event. This narrative review summarises the evidence on four antiplatelet treatments for non-cardioembolic stroke prevention: aspirin, clopidogrel, dipyridamole and ticagrelor. Each of these drugs has a unique mechanism and has been tested as a single agent or in combination. Aspirin, when given early is beneficial and short-term treatment with aspirin and clopidogrel has been shown to be more effective in high-risk TIA / minor stroke. This review concludes by highlighting gaps in evidence, including scope for future trials that could potentially change clinical practice.© Royal College of Physicians 2022. All rights reserved.

24 keywords...

hide…